Transplatin-modified oligonucleotides as modulators of gene expression

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Biochemistry

Background:

• Cisplatin is a clinically effective platinum-based chemotherapy drug.
• Transplatin, a stereoisomer of cisplatin, is clinically inactive.
• Both cisplatin and transplatin interact with DNA.

Purpose of the Study:

• To investigate the DNA binding interactions of transplatin.
• To compare the adducts formed by transplatin with double-stranded and single-stranded DNA.
• To explore the potential therapeutic applications of transplatin-DNA adducts.

Main Methods:

• Review of existing literature on transplatin-DNA interactions.
• Analysis of DNA adduct formation in double-stranded and single-stranded DNA.
• Characterization of intrastrand cross-links at GNG sites.
• Investigation of adduct rearrangement upon DNA duplex formation.

Main Results:

• Transplatin predominantly forms interstrand cross-links with double-stranded DNA.
• Intrastrand cross-links are formed with single-stranded DNA at GNG sites.
• These intrastrand cross-links can isomerize into interstrand cross-links upon formation of a complementary DNA strand.
• This isomerization is triggered by double helix formation.

Conclusions:

• Transplatin's DNA binding mechanism differs significantly from cisplatin.
• The ability of transplatin adducts to rearrange suggests potential for targeted cellular machinery inhibition.
• Further research into transplatin-DNA adducts may yield novel therapeutic strategies.